ZIKV-IN-9

ZIKV-IN-9 (compound 5v) (10 μM; 96 h) reduces ZIKV-induced cytopathic effect by 88.84% and maintains 88.91% cell viability in Vero cells^[1].
ZIKV-IN-9 (96 h) potently inhibits ZIKV in Vero cells with an EC₅₀ of 3.25 μM and no detectable cytotoxicity at tested concentrations^[1].
ZIKV-IN-9 (24 h) inhibits ZIKV in A549 cells with an EC₅₀ of 6.32 μM, a CC₅₀ > 100 μM, and a selectivity index > 15^[1].
ZIKV-IN-9 (10 μM; 24 h) inhibits ZIKV RNA synthesis and envelope protein expression in U251 cells, with an EC₅₀ of 4.30 μM, a CC₅₀ > 40 μM, and a selectivity index > 9^[1].
ZIKV-IN-9 (5-20 μM; 24 h) potently inhibits both ZIKV MR766 and HPF2013 strains in A549 cells in vitro in a dose-dependent manner^[1].
ZIKV-IN-9 (20 μM) mainly targets the early adsorption stage of the ZIKV life cycle in A549 cells and blocks viral particle attachment to the cell surface, confirming its function as a ZIKV entry inhibitor^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.